BNP 和 NTproBNP 市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、檢測地點、應用、地區和競爭格局分類，2020-2030 年預測

2024年全球BNP和NT-proBNP市場規模為19.2億美元，預計2030年將以7.15%的複合年成長率成長至29.1億美元。腦鈉肽（BNP）和N端腦鈉肽前體（NT-proBNP）是心肌細胞在心室擴張或壓力負荷過重時分泌的心臟生物標記物，是心臟衰竭和其他心血管疾病的重要診斷指標。全球心血管疾病發生率的上升和老年人口的不斷成長（老年人尤其容易患心臟疾病）是推動這些診斷檢測市場成長的主要因素。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：客戶之聲

第5章：全球 BNP 與 NTproBNP 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依類型（腦鈉肽、NT-proBNP（N 端腦鈉肽前驅物））
  • 依檢測地點（即時檢測、實驗室檢測）
  • 依應用領域（心肌梗塞、充血性心臟衰竭、急性冠狀動脈綜合症（ACS）、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美BNP和NTproBNP市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲 BNP 和 NTproBNP 市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區 BNP 和 NTproBNP 市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲 BNP 和 NTproBNP 市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美 BNP 與 NTproBNP 市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最新進展

第13章：全球 BNP 和 NTproBNP 市場：SWOT 分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Specim, Spectral Imaging Ltd
• Gentian Diagnostics ASA
• Siemens AG
• PerkinElmer Inc
• Biomerieux SA
• Quidel Corporation
• Bio-Rad Laboratories, Inc.
• F. Hoffman-La Roche Ltd
• BHR Pharmaceuticals Ltd.
• Xiamen Biotime Biotechnology Co., Ltd.

第16章：策略建議

第17章調查會社について,免責事項

The Global BNP And NTproBNP Market, valued at USD 1.92 Billion in 2024, is projected to experience a CAGR of 7.15% to reach USD 2.91 Billion by 2030. Brain Natriuretic Peptide (BNP) and N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) are cardiac biomarkers secreted by cardiomyocytes in response to ventricular stretch or pressure overload, serving as critical diagnostic indicators for heart failure and other cardiovascular conditions. The market for these diagnostic assays is substantially driven by the increasing global incidence of cardiovascular diseases and the expanding geriatric population, which is particularly susceptible to cardiac ailments.

Key Market Drivers

The growth of the Global BNP and NTproBNP Market is significantly influenced by the escalating prevalence of cardiovascular diseases and the expanding geriatric population increasingly susceptible to heart conditions. The rising incidence of cardiovascular diseases necessitates widespread diagnostic and prognostic tools like BNP and NTproBNP assays for early detection and disease management. According to the World Health Organization, in 2022, an estimated 19.8 million people died from cardiovascular diseases, highlighting the profound global health burden these conditions impose. Concurrently, the increasing longevity of populations worldwide contributes to a higher prevalence of age-related cardiac ailments. This demographic shift directly fuels demand for cardiac biomarkers.

Key Market Challenges

The inherent limited specificity of Brain Natriuretic Peptide and N-terminal pro-B-type Natriuretic Peptide tests significantly impedes market expansion. Elevated levels of these biomarkers can arise from various non-cardiac conditions, such as renal failure and pulmonary embolism, potentially leading to false-positive diagnoses and complicating clinical interpretation. This lack of singular diagnostic clarity diminishes confidence in the tests as standalone indicators for heart failure.

Key Market Trends

The expanding integration of point-of-care (PoC) testing represents a significant trend in the global BNP and NTproBNP market by decentralizing diagnostic capabilities and enabling rapid clinical decisions. PoC devices provide immediate results, crucial for managing acute cardiac events and enhancing patient throughput in emergency settings. This trend reflects a broader move towards more accessible and efficient diagnostic pathways. For instance, the American College of Cardiology in a journal scan from August 2024, highlighted a 2-hour strategy for point-of-care high-sensitivity cardiac troponin I testing in suspected acute myocardial infarction, underscoring the drive for expedited cardiac biomarker assessment.

Key Market Players

• Specim, Spectral Imaging Ltd
• Gentian Diagnostics ASA
• Siemens AG
• PerkinElmer Inc
• Biomerieux SA
• Quidel Corporation
• Bio-Rad Laboratories, Inc.
• F. Hoffman-La Roche Ltd
• BHR Pharmaceuticals Ltd.
• Xiamen Biotime Biotechnology Co., Ltd.

Report Scope:

In this report, the Global BNP And NTproBNP Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

BNP And NTproBNP Market, By Type:

• Brain Natriuretic Peptide
• NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide)

BNP And NTproBNP Market, By Location of Testing:

• Point Of Care Testing
• Laboratory Testing

BNP And NTproBNP Market, By Application:

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome (ACS)
• Others

BNP And NTproBNP Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global BNP And NTproBNP Market.

Available Customizations:

Global BNP And NTproBNP Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global BNP And NTproBNP Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Brain Natriuretic Peptide, NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide))
  • 5.2.2. By Location of Testing (Point Of Care Testing, Laboratory Testing)
  • 5.2.3. By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America BNP And NTproBNP Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Location of Testing
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States BNP And NTproBNP Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Location of Testing
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada BNP And NTproBNP Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Location of Testing
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico BNP And NTproBNP Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Location of Testing
      • 6.3.3.2.3. By Application

7. Europe BNP And NTproBNP Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Location of Testing
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany BNP And NTproBNP Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Location of Testing
      • 7.3.1.2.3. By Application
  • 7.3.2. France BNP And NTproBNP Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Location of Testing
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom BNP And NTproBNP Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Location of Testing
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy BNP And NTproBNP Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Location of Testing
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain BNP And NTproBNP Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Location of Testing
      • 7.3.5.2.3. By Application

8. Asia Pacific BNP And NTproBNP Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Location of Testing
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China BNP And NTproBNP Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Location of Testing
      • 8.3.1.2.3. By Application
  • 8.3.2. India BNP And NTproBNP Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Location of Testing
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan BNP And NTproBNP Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Location of Testing
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea BNP And NTproBNP Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Location of Testing
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia BNP And NTproBNP Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Location of Testing
      • 8.3.5.2.3. By Application

9. Middle East & Africa BNP And NTproBNP Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Location of Testing
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia BNP And NTproBNP Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Location of Testing
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE BNP And NTproBNP Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Location of Testing
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa BNP And NTproBNP Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Location of Testing
      • 9.3.3.2.3. By Application

10. South America BNP And NTproBNP Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Location of Testing
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil BNP And NTproBNP Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Location of Testing
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia BNP And NTproBNP Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Location of Testing
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina BNP And NTproBNP Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Location of Testing
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global BNP And NTproBNP Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Specim, Spectral Imaging Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Gentian Diagnostics ASA
• 15.3. Siemens AG
• 15.4. PerkinElmer Inc
• 15.5. Biomerieux SA
• 15.6. Quidel Corporation
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. F. Hoffman-La Roche Ltd
• 15.9. BHR Pharmaceuticals Ltd.
• 15.10. Xiamen Biotime Biotechnology Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer